Patrick Rudy, Mahale Parag, Ackerson Bradley K, Hong Vennis, Shaw Sally, Kapadia Banshri, Spence Brigitte, Feaster Matt, Slezak Jeff, Stern Julie A, Davis Gregg S, Goodwin Gabriella, Lewin Bruno, Lewnard Joseph A, Tseng Hung Fu, Tartof Sara Y
Department of Research & Evaluation, Kaiser Permanente Southern California, United States; Division of Epidemiology and Disease Control, Pasadena, Public Health Department, United States; Epidemic Intelligence Service, Centers for Disease Control and Prevention, United States.
Department of Research & Evaluation, Kaiser Permanente Southern California, United States.
Vaccine. 2025 Apr 19;53:127033. doi: 10.1016/j.vaccine.2025.127033. Epub 2025 Apr 2.
During the 2023-2024 respiratory syncytial virus (RSV) season, vaccination was recommended for adults ≥60 years based on shared clinical decision-making with their healthcare providers. We examined RSV vaccine uptake and characteristics associated with uptake among age-eligible Kaiser Permanente Southern California (KPSC) patients. Our study cohort included all patients ≥60 years from September 23, 2023 (i.e., date RSV vaccination first became available at KPSC; N = 1,003,132) to April 9, 2024 (i.e., end of local RSV season). To identify sociodemographic and clinical characteristics associated with RSV vaccination, we used multivariable robust Poisson regression to estimate the adjusted relative risk (aRR) and 95 % CI. Overall, 7.6 % of patients were vaccinated for RSV. In multivariable regression analyses, those aged 70-79.9 years (aRR: 1.36; 95 % CI: 1.34-1.39) and aged ≥80 years (aRR: 1.35; 95 % CI: 1.32-1.38) were more likely to be vaccinated, compared with those aged 60-69.9 years. Compared with Non-Hispanic White patients, Asian (aRR: 0.95; 95 % CI: 0.93-0.97), Hispanic (aRR: 0.52; 95 % CI: 0.51-0.54), Non-Hispanic Black (aRR: 0.69; 95 % CI: 0.67-0.71), Pacific Islander (aRR: 0.91; 95 % CI: 0.84-0.98), and Native American or Alaska Native (aRR: 0.80; 95 % CI: 0.70-0.92) patients were less likely to be vaccinated. Those in higher neighborhood deprivation quartiles were less likely to be vaccinated (Q2: aRR: 0.86; 95 % CI: 0.85-0.88; Q3: aRR: 0.77; 95 % CI: 0.76-0.79; and Q4: aRR: 0.67; 95 % CI: 0.65-0.68), compared with those in the lowest deprivation quartile. We found low vaccination uptake and identified disparities in vaccination that might exacerbate existing disparities in RSV infection and severe RSV disease among certain populations. CDC's ACIP recently updated their recommendations for all adults 75+ years, and this might begin to address these disparities.
在2023 - 2024年呼吸道合胞病毒（RSV）流行季，建议60岁及以上成年人根据与医疗服务提供者共同做出的临床决策进行疫苗接种。我们调查了符合年龄条件的南加州凯撒医疗集团（KPSC）患者中RSV疫苗的接种情况以及与接种相关的特征。我们的研究队列包括从2023年9月23日（即RSV疫苗在KPSC首次可用的日期；N = 1,003,132）到2024年4月9日（即当地RSV流行季结束）的所有60岁及以上患者。为了确定与RSV疫苗接种相关的社会人口学和临床特征，我们使用多变量稳健泊松回归来估计调整后的相对风险（aRR）和95%置信区间（CI）。总体而言，7.6%的患者接种了RSV疫苗。在多变量回归分析中，与60 - 69.9岁的患者相比，70 - 79.9岁（aRR：1.36；95% CI：1.34 - 1.39）和80岁及以上（aRR：1.35；95% CI：1.32 - 1.38）的患者接种疫苗的可能性更高。与非西班牙裔白人患者相比，亚洲（aRR：0.95；95% CI：0.93 - 0.97）、西班牙裔（aRR：0.52；95% CI：0.51 - 0.54）、非西班牙裔黑人（aRR：0.69；95% CI：0.67 - 0.71）、太平洋岛民（aRR：
